Incyte Corporation INCY
NASDAQ · Healthcare · Biotechnology
$114.63
Close on Fri, 20 Nov 2026 · market value $23.4B
What the price is betting on
Priced for a lot to go rightAt $115, the price assumes revenue grows about 11% a year for five years, from $6B to about $9.2B by FY2030. That is about three times what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 8.3% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than INCY? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$58
Base
$77
Bull
$106
Today $115
- Bear $58. Jakafi's growth keeps fading and the older products keep shrinking, while the newer launches stay too small to fill the gap. The unexplained third-quarter loss points to a weaker earnings base, so free cash flow keeps drifting lower from the depressed twelve-month level.
- Base $77. Newer products such as Opzelura, Zynyz and Minjuvi keep growing and roughly make up for the slowing Jakafi and the shrinking Iclusig and Pemazyre royalties. Free cash flow stays near the recent twelve-month level, well below last year's, because the cause of that gap is still unexplained, and grows only slightly.
- Bull $106. The low twelve-month cash flow proves temporary and recovers toward last year's level, because the third-quarter loss turns out to be largely one-off. Opzelura, Zynyz and the newly approved skin disease therapy then drive fast growth that lifts cash flow well above today's base.
AI-written stories, valued by code from the same model.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$6.2B$6.1B, on the path
- FY2027$6.8B$6.3B, below the path
- FY2028$7.5B$6.6B, below the path
- FY2029$8.3B$4.8B, below the path
- FY2030$9.2B$5.1B, below the path
Each year's revenue at 11% growth from $6B in the 12 months to September 2026.
At a glance
Healthcare · Biotechnology · listed on NASDAQ
- Revenue, FY2025
- $5.1B
- Growth, 3 years a year
- 19%
- Cash margin
- 26%
- Net cash
- $3.5B
- Shares, 3-year change
- −10%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.